New breakthroughs by NPL scientists could transform cancer treatment

Con­necti­cut biotech Hal­da Ther­a­peu­tics, cre­at­ed by Arv­inas founder Craig Crews, has reeled in an­oth­er $126 mil­lion to start clin­i­cal test­ing of its oral mol­e­cules for

Genespire’s GENE202 was developed using the company’s Immune Shielded Lentiviral Vector (ISLV) platform that allows a patient’s liver to produce the therapy throughout its lifetime.